Lee Sung sold $3.2M of CYTK
Lee Sung (EVP, Chief Financial Officer) sold 38,730 shares of CYTOKINETICS INC (CYTK) at $82.30 ($3.19M total) on 2026-06-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Confirms a CFO open-market sale executed under a pre-arranged 10b5-1 plan; typically lower informational content than unscheduled selling.
Market read
Useful for tracking insider behavior, but unlikely to drive a fundamental repricing by itself.
What to watch
Traders should check whether the sale size is unusual relative to prior Form 4 activity and whether there are concurrent insider buys or new company disclosures.
Background
The article is a SEC Form 4 insider transaction disclosure for Cytokinetics, Inc.
Ticker impact
CYTOK insider Lee Sung (CFO) sold 38,730 shares in an open-market transaction at $82.30 on 2026-06-24 under a 10b5-1 plan.
Likely minimal price impact; any effect is short-lived unless paired with other fundamental news.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan; while it confirms selling activity, it does not disclose new operating or financial information.
Market effects
No clear sector read-through; this is company-specific insider liquidity activity.
None.
None.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.
Key entities
- issuerCYTOKINETICS INC
Company whose CFO insider transaction is disclosed on Form 4.
- insiderLee Sung
EVP, Chief Financial Officer; reported open-market sale of CYTK shares under a 10b5-1 plan.
